A gene-therapy product is, at the claim level, a marriage of a therapeutic gene and a vehicle to deliver it. US11883506B2 - "Plakophilin-2 (PKP2) gene therapy using AAV vector," issued January 30, 2024 to Spacecraft Seven, LLC - claims that marriage for a cardiac indication.
The two limitations that define the claim are the transgene and the vector. PKP2 (plakophilin-2) is a gene whose mutation causes arrhythmogenic cardiomyopathy; delivering a functional copy is the therapeutic strategy. The claim recites that PKP2 transgene packaged in an AAV vector. The CPC tags - A61K 48/005 (gene-therapy preparations), C12N 15/86 (viral vector), C12N 2750/14143 (AAV) - capture both halves.
How does this differ from the capsid-engineering estate? The capsid patents claim the vehicle's shell and its tropism, independent of cargo. A product claim like this one claims the specific cargo (PKP2) in a delivery vector for a specific disease. The two layers are complementary: a program needs freedom to operate on both the capsid it uses and the transgene-plus-vector combination it markets.
The scope question is the transgene construct and the indication. A competitor delivering a different gene, or PKP2 by a non-AAV route, may fall outside a claim drawn to PKP2-in-AAV. The claim reaches the specific therapeutic combination, which is why a reader should describe it by its transgene and vector, not merely as 'a gene therapy patent.'
For the landscape, transgene-plus-vector product claims are how rare-disease gene therapies stake their commercial positions. Each disease gene anchors its own small estate, layered over the shared capsid and delivery infrastructure. Freedom-to-operate means clearing the product-level combination separately from the vehicle - the recurring two-layer structure of gene-therapy IP.